atrial myocardium. 8 They are usually thinner compared with LAD bridges (0.1 to 0.3 mm)
and have a width of 10 to 15 mm (range 2 to 30 mm). Occasionally, a bridge may involve a …

Although drug-eluting stents are still the default interventional treatment of coronary artery
disease, drug-coated balloons (DCBs) represent a novel alternative therapeutic strategy in …

Abstract Objectives: The PARAGON-HF (Prospective Comparison of ARNI with ARB Global
Outcomes in HF With Preserved Ejection Fraction) trial is designed to determine the efficacy …

Background In patients with type 2 diabetes, inhibitors of sodium–glucose cotransporter 2
(SGLT2) reduce the risk of a first hospitalization for heart failure, possibly through glucose …

Background The angiotensin receptor–neprilysin inhibitor sacubitril–valsartan led to a
reduced risk of hospitalization for heart failure or death from cardiovascular causes among …

Importance Uncertainty remains about the efficacy of folic acid therapy for the primary
prevention of stroke because of limited and inconsistent data. Objective To test the primary …

BACKGROUND: There are several reports that engrafted mesenchymal stem cells (MSCs)
stimulate angiogenesis in the ischemic heart, but the mechanism remains controversial. We …

Neovascularization induced by vascular endothelial growth factor (VEGF) represents an
appealing approach for treating ischemic heart disease. However, VEGF therapy has been …

BACKGROUND In autopsy, myocardial bridging is a common finding. With coronary
angiography, a systolic compression, mainly of the left anterior descending coronary artery …

Importance Additional treatments are needed for heart failure with reduced ejection fraction
(HFrEF). Sodium-glucose cotransporter 2 (SGLT2) inhibitors may be an effective treatment …